Drugs.com is the most popular, comprehensive and up-to-date source of drug information online. Providing free, peer-reviewed, accurate and independent data on more than 24,000 prescription drugs, over-the-counter medicines & natural products.
FDA Approves Updated Altuviiio Label With Expanded Pediatric Data Confirming Highly Effective Bleed Protection in Children With Hemophilia
The US Food and Drug Administration (FDA) has updated the label for Altuviiio® [Antihemophilic Factor (Recombinant), Fc-VWF-XTEN Fusion Protein-ehtl]...
San Francisco Set to Ban 'Forever Chemicals' in Firefighter Gear
San Francisco is on the verge of passing a ban on "forever chemicals" in the protective clothing firefighters wear while battling blazes.City lawmakers...
More Studies Support Wegovy's Long-Term Weight-Loss Benefits
Semaglutide -- the active ingredient in the blockbuster weight-loss drugs Ozempic and Wegovy -- can produce long-term weight and heart health benefits,...
Americans With Private Insurance May Pay More for Hospital Stay
Having private insurance may not be all it is cracked up to be when it comes to hospital bills, new research warns.In a report published Monday by the...
Patients Over 80 Still Benefit From Treatment for AML Blood Cancer
Seniors over 80 with acute myeloid leukemia can safely and effectively take the standard targeted therapy for the blood cancer, a new study finds.The oral...
Mabwell Announces Clinical Trial Progress of 9MW2821 in Triple-Negative Breast Cancer
SHANGHAI, May 13, 2024, Mabwell, an innovation-driven biopharmaceutical company with entire industry chain, announced the progress of the clinical study...
All-Cause Mortality Risk Up for Men With Low Testosterone
The risk for all-cause mortality is increased for men with low testosterone, high luteinizing hormone, or very low estradiol, according to a review published...
High Predictability for Measles Antibody Dynamics Discernible From Birth
At the individual level, there is high predictability for measles antibody dynamics from birth, according to a study published online May 13 in Nature...
DDW: 1999 to 2020 Saw Rise in Incidence of Colorectal Cancer in People Under 45
For individuals aged younger than 45 years, the incidence of colorectal cancer increased considerably from 1999 to 2020, with a 333 percent increase among...
Physicians With Disabilities May Experience Depersonalization
Physicians with disabilities (PWDs) are significantly more likely to experience depersonalization but not emotional exhaustion when compared with their...
FDA Safety Communication: Do Not Use Cue Health’s COVID-19 Tests Due to Risk of False Results
The U.S. Food and Drug Administration (FDA) is warning home test users, caregivers, and health care providers not to use Cue Health’s COVID-19 Tests...
Geisinger enrolls first patient in amyloid cardiomyopathy trial
DANVILLE, Pa., May 10, 2024. Cardiologist Brendan Carry, MD, and a team of Geisinger physicians have enrolled the first patient in the U.S. into a cardiac...
There's a New Set of COVID Variants Called FLiRT: What You Need to Know
The virus behind COVID has mutated again, this time producing variants nicknamed FLiRT, the U.S. Centers for Disease Control and Prevention (CDC) has reported. The...
Recently Added
Recently added consumer and prescribing information: Myhibbin, Rezenopy, Libervant, Beqvez, Xolremdi, Pivya, Xromi, Risvan, Voydeya, Winrevair
For Consumers
- Cerner Multum Drug Information
- Micromedex Advanced Consumer
- Natural Product Information for the Consumer
For Professionals
- FDA Professional Information
- Professional Patient Advice
- ASHP Monographs (AHFS DI)
- Micromedex Carenotes
- Natural Product Information
For Researchers
Latest FDA New Drug Approvals
- Myhibbin Myhibbin (mycophenolate mofetil) is an antimetabolite immunosuppressant used for the prophylaxis of organ rejection.
- Libervant Libervant (diazepam) is a buccal film formulation of the benzodiazepine diazepam that may be given to treat children aged 2 to 5 years with...
- Xolremdi Xolremdi (mavorixafor) is a CXC chemokine receptor 4 (CXCR4) antagonist indicated in patients 12 years of age and older with WHIM syndrome...
Drugs in Development (Not yet approved)
- Yutrepia Yutrepia (treprostinil) is an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) to...